Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMMUNIC, INC. Director's Dealing 2017

Jun 15, 2017

10196_dirs_2017-06-15_9c3ee322-b579-4840-b9db-68cb77176ca2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VITAL THERAPIES INC (VTL)
CIK: 0001280776
Period of Report: 2017-06-14

Reporting Person: Winters Terence E. (Director, Co-Chairman and CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-06-14 Common Stock P 10000 $3.0981 Acquired 194966 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 119964 Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.075 to $3.10. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (1) to this Form 4.